Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

Vijay Ramakrishnan, Michael Timm, Jessica L. Haug, Teresa K. Kimlinger, Timothy Halling, Linda E. Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei, Shaji Kumar

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin'. Together they form a unique fingerprint.

Medicine & Life Sciences